Agenda

The Cell & Gene Meeting on the Mesa is a three-day conference combining discussions between key opinion leaders, senior executives and top academic researchers. The program also includes 60+ presentations by the field’s most promising companies and poster abstracts by leading scientists from around the globe.

This agenda will be updated continuously so check back soon for new speaker additions!

CGMOM17-Agenda-Day1-495x195

7:00am – 9:30am | REGISTRATION AND BREAKFAST
7:15am – 8:45am | CONCURRENT WORKSHOPS

DOING BUSINESS IN JAPAN WORKSHOP: BEYOND JAPAN’S REGULATORY RENOVATION

Magnolia Room | 7:15am – 8:45am
In Partnership with the Forum for Innovative Regenerative Medicine (FIRM)

DOING BUSINESS IN JAPAN WORKSHOP
Beyond Japan’s Regulatory Renovation

GENE THERAPY MANUFACTURING WORKSHOP

Learning Theater | 7:15am – 8:45am
Sponsored by Aldevron, Brammer Bio and MaxCyte

GENE THERAPY MANUFACTURING WORKSHOP

Session 1: Viral Gene Therapy Manufacturing
The manufacture of gene transfer vectors used for in vivo and ex vivo delivery is complex. The panelists will address technologies and platforms used to manufacture viral vector systems, critical raw materials, analytical technologies used to characterize viral vectors, and accessing clinical and commercial manufacturing capacity.

Chair:
Richard Snyder, Ph.D., Founder and Chief Scientific Officer, Brammer Bio

Speaker:
James Brown, Ph.D., VP, Corporate Development, Aldevron

Session 2: Cell-based Gene Therapy Manufacturing
The experts on this panel will discuss challenges associated with the delivery of genes via live cells. Topics will include viral vectors as ancillary materials, expanding draggable targets to include neo-antigens and meeting the challenges of commercial-scale autologous cell manufacturing.

Chair:
Jessica Carmen, Ph.D., Director of Business Development, Cellular Therapy Partnerships, MaxCyte

DEVELOPMENT OF CELLULAR THERAPIES WORKSHOP

Ballroom 2 | 7:15am – 8:45am
Sponsored by QuintilesIMS

DEVELOPMENT OF CELLULAR THERAPIES WORKSHOP
Real World Examples for Overcoming the Unique Complexities and Development Challenges Faced in Regenerative Medicine

The development of cellular and gene-based therapies face many unique challenges that preclude a linear application of clinical trial development best practices. Featuring global leaders in clinical trial management and operations, this workshop will highlight the unique challenges faced in the development of these regenerative medicine therapies. Discussion will include the convergence of best practices in translational techniques with clinical trial development practices to incorporate challenges associated with limited patient sets for rare diseases, restricted quantities of clinical trial materials, and adaptive trial designs to improve understanding of dose ranges throughout the clinical trial process. In addition, tested and emerging models for overcoming these challenges will be discussed in a round robin format.

Session 1: Development of Cellular Therapies
Pragmatic Solutions for Overcoming the Unique Complexities and Challenges Faced in Regenerative Medicine from Early Clinical Development Through Commercialization
It is an accepted wisdom that a high degree of technical and operational expertise is needed for successful product development in regenerative medicine (RMx), specifically in cell and gene therapies. But what factors are actually at play in RMx therapy development that require this expertise, and what levers can be pulled to solve these challenges? RMx trials layer the challenges of the most complex trials for traditional therapies (i.e., indication-specific challenges) with unique complexities inherent to RMx. The key to executing a successful trial is solving all of these issues at the outset and operationalizing these solutions throughout. Discussion points will include trial design, site selection and trial operation as well as patient recruitment and retention.

Chair:
Laura Marquis, VP and Global Head, Emerging Biopharma, QuintilesIMS

Speaker:
Timothy Schroeder, CEO, CTI Clinical Trial and Consulting Services

Session 2: Informing Clinical Design with an Eye Towards Commercial Success
Despite their curative potential, cell and gene therapies continue to face immense barriers to commercialization. Successfully demonstrating product value upon launch and justifying price points across stakeholders with differing needs and priorities requires an informed trial design with an eye towards commercialization. This panel will explore the ways in which cell and gene companies can leverages clinical insights for optimized value demonstration at launch. Discussion points will include trial design with the end in mind, ways of leveraging secondary endpoints beyond safety and efficacy as a critical component of trial design and anticipating operational and manufacturing limitations.

Chair:
Rick Sax, M.D., SVP, Advisory Services, QuintilesIMS

9:00am | GENERAL SESSION AND PARTNERING OPENS
9:00am – 9:15am WELCOME REMARKS {Ballroom 1}
Speaker:
Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine (ARM)
9:15am – 10:15am PLENARY SESSION: IMPLICATIONS OF COMMERCIALIZATION: WHAT DOES APPROVAL MEAN? {Ballroom 1}
Chair:
Amy DuRoss, CEO, Vineti
Speaker:
Bob Azelby, EVP, Chief Commercial Officer, Juno Therapeutics
10:15am – 10:45am | MORNING BREAK
Sponsored by Cellular Dynamics International and Draper
10:30am – 12:00pm | CONCURRENT TRACKS
SPOTLIGHT: TISSUE ENGINEERING {Ballroom 1}
10:45am – 11:15am
Chair:
Tom Novak, Ph.D., VP, Strategic Partnerships, Cellular Dynamics International
Speakers:
Miguel Forte, M.D., Ph.D., Chief Medical Officer, Bone Therapeutics
Adam Gridley, President and CEO, Histogenics
COMPANY PRESENTATIONS {Ballroom 2}
10:45am – 11:00am Renova Therapeutics
11:00am – 11:15am Juventas Therapeutics
11:15am – 11:30am Capricor Therapeutics
11:30am – 11:45am Cesca Therapeutics
11:45am – 12:00pm Lysogene
COMPANY PRESENTATIONS {Ballroom 1}
11:15am – 11:30am Abeona Therapeutics
11:30am – 11:45am Audentes Therapeutics
11:45am – 12:00pm CRISPR Therapeutics
12:00pm – 1:15pm | LUNCH
Sponsored by Vineti
1:15pm – 3:30pm | CONCURRENT TRACKS
PANEL: NAVIGATING REGENERATIVE MEDICINE TECHNOLOGY ASSESSMENT AND REIMBURSEMENT IN NORTH AMERICA AND EUROPE: CHARTING A PATH TO PATIENT ACCESS {Ballroom 1}
1:15pm – 2:15pm
As 800+ regenerative and advanced therapies are en route to market, global health technology assessment and reimbursement processes represent one of most critical hurdles to patient access and product commercial success. How and in what ways would value assessment/HTA differ for technologies with transformative or curative potential? What are the options if therapies do not fit “neatly” into existing reimbursement structures? How will global health systems address payment for single administration therapies? This panel will present payer panelists from North America and Europe with rare disease and oncology case examples and explore acceptance and uptake drivers spanning HTA evaluation requirements, fit into existing reimbursement systems and payment for complex, single administration therapies.
Sponsored by Evidera
Chair:
Eric Faulkner, VP, Precision and Transformative Technology Solutions, Value Demonstration, Access and Commercial, Evidera
Speakers:
Jim Cross, M.D., Former Head, National Medical Policy and Operations, Aetna
John Goldenring, M.D., Western Regional Medical Director for Care Management, Anthem
COMPANY PRESENTATIONS {Ballroom 2}
1:15pm – 1:30pm Sentien Biotechnologies
1:30pm – 1:45pm Medeor Therapeutics
1:45pm – 2:00pm Promethera Biosciences
2:00pm – 2:15pm Vivet Therapeutics
COMPANY PRESENTATIONS {Ballroom 1}
2:15pm – 2:30pm Fate Therapeutics
2:30pm – 2:45pm Bellicum Pharmaceuticals
2:45pm – 3:00pm Adaptimmune
3:00pm – 3:15pm bluebird bio
3:15pm – 3:30pm MolMed
COMPANY PRESENTATIONS {Ballroom 2}
2:15pm – 2:30pm Bone Therapeutics
2:30pm – 2:45pm DiscGenics
2:45pm – 3:00pm MEDIPOST America
3:00pm – 3:15pm Fibrocell
3:15pm – 3:30pm Histogenics
10:15am – 10:45am | MORNING BREAK
Sponsored by Cellular Dynamics International and Draper
4:00pm – 6:00pm | CONCURRENT TRACKS
PANEL: GENE THERAPY: BUILDING THE GENE MEDICINE PIPELINE THROUGH NEXT GENERATION TECHNOLOGIES {Ballroom 1}
4:00pm – 5:00pm
This panel will explore how gene therapy product developers are strategically building the clinical pipeline utilizing next generation technologies. Discovery and design of new highly trophic viral capsids, stronger and shorter synthetic promoters and tightly inducible regulatory elements are examples of the novel components incorporated into the second-generation lead candidates. Topics and discussion will include optimization of the pipeline to enhance tissue specificity, transduction and vector tropism, generate clinically relevant transgene expression levels, solve first generation vector capacity issues, potentially modulate immunity and to enhance safety.
Chair:
Sue Washer, President and CEO, AGTC
Speakers:
Donna Armentano, Ph.D., Executive Director, External Research and Development Innovation, Gene Therapy, Pfizer
Sheila Mikhail, Founder, President and CEO, AskBio; Founder and Former CEO, Bamboo Therapeutics
Thomas Wilton, Chief Business Officer, LogicBio Therapeutics
COMPANY PRESENTATIONS {Ballroom 2}
4:00pm – 4:15pm Cynata Therapeutics
4:15pm – 4:30pm BlueRock Therapeutics
4:30pm – 4:45pm Cellular Dynamics International
4:45pm – 5:00pm Healios K.K.
COMPANY PRESENTATIONS {Ballroom 1}
5:00pm – 5:15pm TiGenix
5:15pm – 5:30pm MiMedx
5:30pm – 5:45pm Mesoblast
5:45pm – 6:00pm Vericel
COMPANY PRESENTATIONS {Ballroom 2}
5:00pm – 5:15pm Terumo BCT
5:15pm – 5:30pm Sigilon
5:30pm – 5:45pm jCyte
5:45pm – 6:00pm Acucela
6:00pm | PARTNERING CLOSES
6:30pm – 9:30pm | GALA RECEPTION
Sponsored by BlueRock Therapeutics and CCRM

CGMOM17-Agenda-Day2-495x105

7:00am – 9:30am | REGISTRATION AND BREAKFAST
Sponsored by TrakCel
7:15am – 8:45am | CONCURRENT WORKSHOPS

HEALTH TECHNOLOGY ASSESSMENT WORKSHOP

Magnolia Room | 7:15am – 8:45am

HEALTH TECHNOLOGY ASSESSMENT WORKSHOP
Mock Technology Appraisal for Regenerative Medicine: Perspectives from U.S. and EU Health Technology Assessment (HTA) Experts

As a follow-up to the October 5th Technology Assessment Panel, this workshop will take a deeper dive into the challenges HTAs will face when assessing a one-time, potentially transformative therapy. Participants will include experts in HTA from both the U.S. and EU. To stimulate critical thinking, an ‘exemplar’ case study incorporating a hypothetical product will be developed and provided to panel members for their consideration in advance of the meeting. The case study will include target indication and population, a brief summary of current standard of care and what is known about likely comparators, expected evidence generated from trial program and other supporting data. Panel members will present their initial assessment of the product based on the value framework they typically apply. Their feedback is expected to encompass:

  • Strengths and weaknesses of existing evidence base
  • Applicability of comparators
  • Key areas of uncertainty as related to value demonstration

The workshop will then involve participant and audience feedback on creative approaches to fill the identified gaps.

Chair:
Doug Danison, VP Access, Value and Evidence Strategy, bluebird bio

Speakers:
Bill Dreitlein, Pharm.D., Director of Pharmaceutical Policy, Institute for Clinical and Economic Review (ICER)
Clark Paramore, Head of Value Demonstration, bluebird bio

HELPING YOUR CELL THERAPY GO GLOBAL WORKSHOP

Learning Theater | 7:15am – 8:45am
Lead Sponsor: PCT, A Hitachi Group Company
Supporting Sponsors: Irvine Scientific and MilliporeSigma

HELPING YOUR CELL THERAPY GO GLOBAL WORKSHOP

With a robust pipeline of cell therapies steadily advancing towards approval and commercialization, developers are increasingly considering and implementing strategies to effectively reach a global patient population. But going global can be fraught with uncertainty and present added risk.

This expert panel will explore a number of important questions including:

  • What are the benefits to going global in terms of cell therapy development and commercialization strategies?
  • How are developers establishing strategies and capacity for global development and manufacturing?
  • What considerations go into the choice to expand geographic reach for a product candidate?
  • Can global strategy wait until the first commercial approval is achieved? What is the optimum timing?
  • What are the pitfalls or challenges of a global strategy and how can they be avoided?

Chair:
Robert Preti, Ph.D., CEO and President, PCT, A Hitachi Group Company; General Manager, Hitachi Chemical Regenerative Medicine Business Sector

Speakers:
Marlin Frechette, Director, Regulatory Affairs/Quality Systems, Irvine Scientific
David Mazzo, Ph.D., CEO and Director, Caladrius Biosciences
Julie Murrell, Ph.D., Head of Cell Therapy Bioprocessing, MilliporeSigma

 

LOGISTICS, AUTOMATION AND STANDARDS WORKSHOP

Ballroom 2 | 7:15am – 8:45am
Sponsored by Cryoport and World Courier

LOGISTICS, AUTOMATION AND STANDARDS WORKSHOP

Session 1: Systems Integration Logistics Management
Systems integration is defined as the process of aggregating component sub-systems into one cooperating system that is able to deliver the overarching functionality and act as a coordinated whole. This integration process includes both physical and informatics process integration, and can include the following functions: Patient Recruitment, Scheduling, Logistics, Analysis, Manufacturing, Distribution, and Reimbursement. This panel will discuss critical process integration recommendations for seamless launch of cell-based therapies.

Chair:
Mark Sawicki, Chief Commercial Officer, Cryoport

Speakers:
Layne Martin, VP/General Manager, Supply Chain Solutions, McKesson Specialty Health
Phil Vanek, Ph.D., GM Cell Bioprocessing, GE Healthcare

Session 2: Scale-up and Out: The Role of Transportation and Standards
To ensure integrity of the product, patient safety and successful commercialization, cell therapies call for heightened transport and logistical standards. Planning a supply chain which incorporates these early, during clinical phases, pays dividends as production scales up and out into commercialization. This is particularly true for supply chains which cross international boundaries and where integration with patient services, manufacturing and reimbursement are critical. This panel will discuss best practices and recommendations for building a supply chain aligned to your strategic commercialization goals.

Chair:
James Klingelheofer, North American Sales Director, World Courier, an AmerisourceBergen company
Speaker:
Claudia Zylberberg, Founder and CEO, Akron Biotech

9:00am | GENERAL SESSION AND PARTNERING OPENS
9:00am – 9:15am WELCOME REMARKS {Ballroom 1}
THE GENE EDITING CHALLENGE: VALIDATING PLATFORM TECHNOLOGIES {Ballroom 1}
9:15am – 10:15am
For any emerging biotech company with a novel platform technology, proving validation and establishing trust in that platform is essential to building momentum and long-term success. Trust must be established with multiple stakeholders – potential licensing partners and investors, regulators and clinicians and foremost with patients. In the gene editing space, these concerns are heightened by the unprecedented manipulation of the body’s basic building blocks. Increased understanding in gene editing technologies across all stakeholders has the ability to open doors for additional discovery, development and commercialization efforts. As companies in this space advance, all parties must maintain discipline in limiting patient risk and validating utility of these platforms in order to enable continued expansion of the field. This panel brings together top leaders representing the most prominent technologies across the gene editing landscape to discuss the applicability of their platforms, potential hurdles to advancement and the implications of pursuing various indications as these technologies move toward commercialization.
Sponsored by ClearView Healthcare Partners
Chair:
Debbie Zhuang, Principal, ClearView Healthcare Partners
Speakers:
Katrine Bosley, CEO, Editas Medicine
Matthew Kane, Co-Founder and CEO, Precision Biosciences
Sandy Macrae, Ph.D., President and CEO, Sangamo Therapeutics
Albert Seymour, Ph.D., Chief Scientific Officer, Homology Medicines
COMPANY PRESENTATIONS {Ballroom 2}
9:15am – 9:30am Caladrius Biosciences
9:30am – 9:45am Semma Therapeutics
9:45am – 10:00am ViaCyte
10:00am – 10:15am Orbsen Therapeutics
10:15am – 10:45am | MORNING BREAK
Sponsored by Cellular Dynamics International and Draper
10:45am – 11:45am | CONCURRENT TRACKS
FDA FEATURED TALK {Ballroom 1}
10:45am – 11:00am
Speaker:
Wilson Bryan, M.D., Director, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
COMPANY PRESENTATIONS {Ballroom 2}
10:45am – 11:00am American Gene Technologies
11:00am – 11:15am AVROBIO
11:15am – 11:30am Homology Medicines
11:30am – 11:45am Orchard Therapeutics
11:45am – 12:00pm Precision BioSciences
PANEL: ACCELERATING REGULATORY DEVELOPMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS FOR PATIENTS IN NEED {Ballroom 1}
11:00am – 12:00pm
This panel features distinguished regulators from the U.S., EU and Japan as they share their views on how different expedited programs are supporting innovation and accelerating advanced therapy product developments for patients with significant unmet needs. Panelists will discuss how to improve the regulatory process and lessons learned from recent experience in this rapidly emerging field, including real world evidence generation. Looking to the future, panelists will share ideas on how to bridge the gap with science and the next step in a product life-cycle. Both in terms of process and scientific review and advice, panelists will be asked whether there are things industry could do better, and whether there are tools that could benefit all regions to improve efficiency in the regulatory authority/sponsor dialog.
Sponsored by Cell and Gene Therapy Catapult and Janssen R&D
Chair:
Jacqueline Barry, Ph.D., Chief Clinical Officer, Cell and Gene Therapy Catapult
Speakers:
Wilson Bryan, M.D., Director, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
Yoshiaki Maruyama, Ph.D., Review Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA)
Daisaku Sato, Ph.D., Director, Safety Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare (MHLW)
11:45am – 1:00pm | LUNCH
Sponsored by StemoniX
1:00pm – 2:45pm | CONCURRENT TRACKS
SPOTLIGHT: FINANCING THE CELL AND GENE THERAPY SECTOR {Ballroom 1}
1:15pm – 1:45pm
Chair:
Morrie Ruffin, Managing Director, Alliance for Regenerative Medicine (ARM); Managing Partnering, Adjuvant Partners
Speaker:
Graham Walmsley, M.D., Ph.D., Investment Professional, Versant Ventures
COMPANY PRESENTATIONS {Ballroom 2}
1:15pm – 1:30pm TxCell
1:30pm – 1:45pm Cell Medica
1:45pm – 2:00pm CellSeed
2:00pm – 2:15pm GammaDelta Therapeutics
2:15pm – 2:30pm PDC*Line Pharma
2:30pm – 2:45pm WindMIL Therapeutics
COMPANY PRESENTATIONS {Ballroom 1}
1:45pm – 2:00pm Intellia Therapeutics
2:00pm – 2:15pm REGENXBIO
2:15pm – 2:30pm Sangamo Therapeutics
2:30pm – 2:45pm AGTC
10:15am – 10:45am | MORNING BREAK
Sponsored by Cellular Dynamics International and Draper
3:15pm – 5:30pm | CONCURRENT TRACKS
PANEL: IPSCs FOR THERAPEUTIC APPLICATIONS  {Ballroom 1}
3:15pm – 4:15pm
This panel will highlight the clinical potential of IPSCs and the technical challenges that companies in this area are facing on the path to commercialization. The discussion will review the transition of new therapies based upon iPSCs from research into the clinic. It will also examine the barriers to the development of the industry and how these can be removed to accelerate growth.
Chair:
Keith Thompson, CEO, Cell and Gene Therapy Catapult
Speakers:
Ross Macdonald, Ph.D., Managing Director and CEO, Cynata Therapeutics
Emile Nuwaysir, Ph.D., CEO, BlueRock Therapeutics
Yuzo Toda, Chairman, Forum for Innovative Regenerative Medicine (FIRM); Senior Executive VP and Chief Technical Officer, Director, FUJIFILM Corporation
COMPANY PRESENTATIONS {Ballroom 2}
3:15pm – 3:30pm B-MoGen Biotechnologies
3:30pm – 3:45pm Synpromics
3:45pm – 4:00pm Benitec Biopharma
4:00pm – 4:15pm 4D Molecular Therapeutics
COMPANY PRESENTATIONS {Ballroom 1}
4:15pm – 4:30pm Oxford BioMedica
4:30pm – 4:45pm Athersys
4:45pm – 5:00pm BioTime
5:00pm – 5:15pm Asterias Biotherapeutics
5:15pm – 5:30pm Osiris Therapeutics
COMPANY PRESENTATIONS {Ballroom 2}
4:15pm – 4:30pm StemBioSys
4:30pm – 4:45pm Universal Cells
4:45pm – 5:00pm BioStage
5:00pm – 5:15pm SCM Lifescience
5:15pm – 5:30pm RoosterBio
5:30pm | PARTNERING CLOSES

CGMOM17-Agenda-Day2-PF-592x105

5:45pm | PUBLIC FORUM OPENS
6:00pm – 6:45pm FEATURED PRESENTATION: TOWARDS A BETTER UNDERSTANDING OF NEUROPSYCHIATRIC DISORDERS: THE ROLE OF SYNAPSES
Introduction By:
Donna Skerrett, M.D., Chief Medical Officer, Mesoblast
Featured Speaker and Nobel Laureate:
Thomas Südhof, M.D., Professor, Molecular and Cellular Physiology; Professor, Neurology and Neurological Sciences; Professor, Psychiatry and Behavioral Science, Stanford University; Investigator, Howard Hughes Medical Institute
6:45pm – 7:30pm | RECEPTION AND NETWORKING
Sponsored by Mesoblast
7:30pm | PUBLIC FORUM CLOSES

CGMOM17-Agenda-Day3-530x105

7:00am – 8:00am | REGISTRATION AND BREAKFAST
Sponsored by the Sanford Stem Cell Clinical Center at UC San Diego Health
8:00am | GENERAL SESSION
8:00am – 8:15am WELCOME REMARKS
Speaker:
Alysson Muotri, Ph.D., Chair, Scientific Symposium Steering Committee; Director, Stem Cell Program; Professor, Department of Pediatrics and Cellular Molecular Medicine, UC San Diego
8:15am – 8:55am MORNING KEYNOTE SPEAKER
Keynote Speaker:
Luigi Naldini, M.D., Ph.D., Professor, Cell and Tissue Biology, Vita-Salute San Raffaele University; Director and Head, San Raffaele Telethon Institute for Gene Therapy
8:55am – 10:15am PANEL: ADVANCES IN CAR-T CELL THERAPY
Chair / Introduction By:
Catriona Jamieson, M.D., Ph.D., Associate Professor of Medicine, Division of Hematology-Oncology; Chief, Division of Regenerative Medicine; Deputy Director, Sanford Stem Cell Clinical Center; Co-Leader, Hematologic Malignancies Program; Director, Stem Cell Research, Moores UC San Diego Cancer Center
Speakers:
Christine Brown, Ph.D., Heritage Provider Network Professor in Immunotherapy; Associate Director, T Cell Therapeutics Research Laboratory, Beckman Research Institute of City of Hope
Jeremy Rich, M.D., Associate Professor of Medicine, UC San Diego
Travis Young, Ph.D., Principal Investigator of Immuno-Oncology, California Institute for Biomedical Research (CALIBR)
10:15am – 10:45am | MORNING BREAK
Sponsored by Cellular Dynamics International and Draper
10:15am – 10:40am | POSTER VIEWING
10:40am – 12:00pm PANEL: PROGENITORS AND STEM CELLS
Chair / Introduction By:
Martin Friedlander, M.D., Ph.D., Professor, Department of Molecular Medicine, The Scripps Research Institute
Speaker:
Kevin Eade, Ph.D., Staff Scientist, The Lowy Medical Research Institute
12:00pm – 1:15pm | LUNCH
Sponsored by the Sanford Stem Cell Clinical Center at UC San Diego Health
12:00pm – 1:15pm | POSTER VIEWING
1:15pm – 2:35pm PANEL: THE USE OF TISSUE ORGANOIDS IN SEVERAL BIOLOGICAL APPLICATIONS
Tri-dimensional models can best mimic human tissues in a dish. On this panel, the audience will hear how investigators are deriving live human 3D organoids in a dish to understand human development, perform disease modeling and for potential therapeutic applications.
Chair / Introduction By:
Alysson Muotri, Ph.D., Director, Stem Cell Program; Professor, Department of Pediatrics and Cellular Molecular Medicine, UC San Diego
Speakers:
Alysson Muotri, Ph.D., Director, Stem Cell Program; Professor, Department of Pediatrics and Cellular Molecular Medicine, UC San Diego
Helen Bateup, Ph.D., Assistant Professor of Neurobiology, UC Berkeley
Xin Sun, Ph.D., Professor of Pediatrics, UC San Diego
Karl Wahlin, Ph.D., Assistant Professor of Ophthalmology, UC San Diego
10:15am – 10:45am | MORNING BREAK
Sponsored by Cellular Dynamics International and Draper
2:35pm – 3:00pm | POSTER VIEWING
3:00pm – 4:20pm PANEL: IMAGING STEM CELLS IN REGENERATION AND CANCER
Chair / Introduction By:
Tannistha Reya, Ph.D., Professor, Pharmacology and Medicine, UC San Diego
Speakers:
Tony Hunter, Ph.D., American Cancer Society Professor, Molecular and Cell Biology Laboratory; Renato Dulbecco Chair, Salk Institute for Biological Studies
Leanne Jones, Ph.D., Professor, Department of Molecular, Cell and Developmental Biology, UC Los Angeles
Jeffrey Rosen, Ph.D., Professor and Vice-Chair, Molecular and Cellular Biology, Baylor University
4:20pm – 5:00pm AFTERNOON KEYNOTE SPEAKER
Keynote Speaker:
Kelly Frazer, Ph.D., Director, Institute for Genomic Medicine; Founding Chief, Division of Genome Information Sciences, Department of Pediatrics, UC San Diego
5:00pm – 6:30pm | NETWORKING RECEPTION
Sponsored by the Sanford Stem Cell Clinical Center at UC San Diego Health
5:00pm – 6:30pm | POSTER VIEWING
6:30pm | SCIENTIFIC SYMPOSIUM CLOSES